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Abstract
We present the clinical, laboratory, radiological and pathological findings in the case and review the literature. Our patient, a 37-year-old
woman of short stature, was referred because of musculoskeletal pain. After primary evaluation, she underwent treatment with calcium
and vitamin D supplement with the diagnosis of osteomalacia in Turner’s syndrome. The rise of serum calcium during medical therapy,
which was an unusual finding, attracted the clinician’s attention to another underlying disorder. Further evaluation revealed primary
hyperparathyroidism due to an adenoma of the parathyroid gland. Even though this is a rare diagnosis, its presence should be considered
in any patient with Turner’s syndrome presenting with severe osteoporosis and a rise in serum calcium during treatment.
(Pol J Endocrinol 2008; 59 (3): 232–234)
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Streszczenie
Przedstawiony przez autorów opis przypadku zawiera ocenę kliniczną, wyniki badań laboratoryjnych, radiologicznych, patomorfologicz-
nych 37-letniej kobiety, u której początkowo rozpoznano osteomalację przebiegu zespołu Turnera i zastosowano suplementację wapnia
i witaminy D. Ze względu na szybką progresję Ca we krwi rozszerzono diagnostykę, rozpoznając dodatkowo nadczynność przytarczyc
spowodowaną gruczolakiem tego narządu.
 (Endokrynol Pol 2008; 59 (3): 232–234)
Słowa kluczowe: pierwotna nadczynność przytarczyc, zespół Turnera, choroba kości
Case Presentation
A 37-year-old woman was referred to an endocrinolo-
gist because of low bone density in radiography. She
had a long history of musculoskeletal pain, without frac-
tures or nephrolithiasis. She had polyuria, polydypsia
and non-significant weight loss (2–3 kg over two years).
For six years she has experienced secondary amenorr-
hea, addressed by hormone therapy.
In physical examination, blood pressure was 90/60
mm Hg, pulse rate = 80/min, height = 131 cm, weight
= 36 kg. She had no obvious neck mass or goitre and
examination of her chest and abdomen showed nor-
mal findings. The proximal muscular force of the legs
was 4/5.
The primary laboratory profile included a complete
blood count (CBC), fasting blood sugar (FBS), blood urea
nitrogen (BUN) and creatinine, liver function test and
lipid profile, and was normal. Serum calcium (Ca), pho-
sphorus (P) and alkaline phosphatase (Alk. Ph) contents
were as follows; Ca = 10 mg/dl (8.6–10.3), Pi = 2.7 mg/dl
(2.5–5), Alk Ph. = 1010 IU/L (70–310), FSH = 118 IU/L
(follicular phase = 3.5–9.7), LH = 65 IU/L (follicular
phase = 1.7–8.9).
A bone mineral density scan was performed. Spinal
measurements showed an adult T-score of –4.5, which
was in the osteoporotic range, and an age-matched
Z-score of –3.5. Hip measurement results indicated
a T-score of –3.3, in the osteoporotic range, and an age-
matched Z-score of –2.5.
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In view of the patient’s short stature, high gonado-
tropin level, secondary amenorrhea and low bone den-
sity, further evaluation was performed, including a de-
termination of karyotype. This confirmed the diagno-
sis of mosaic Turner’s syndrome (TS) (mos 46,X,i(X) (q10)
[14]/45,X [6]). The pertinent paraclinical studies, inclu-
ding echocardiography, ultrasonography of the urina-
ry system and thyroid function test, were normal. An
occult blood test was negative. In addition, audiometry
demonstrated a sensory neural defect in the left ear.
With a diagnosis of osteomalacia she underwent
medical therapy with calcium carbonate (1 g daily) and
calcitriol (0.25 mcg twice daily). Total serum calcium in-
creased during follow-up (from 10 mg/dl to 11.3 mg/dl).
Three months later, in an assessment of hypercalcaemia,
the results of laboratory findings were as follows:
Ca = 11.4 mg/dl (8.6–10.3) P = 2.6 mg/dl (2.5–5) Alk.
Ph. = 802 IU/L (70–310) Intact PTH = 188 pg/ml (10–70),
and Ca (24 h urine) = 465 mg/24 h (female < 250). Hyper-
calcaemia persisted, despite discontinuation of the oral
calcium and calcitriol.
Skull and chest radiographies were unremarkable.
In radiography of both hands, there was no abnormali-
ty apart from osteopoenia.
A 99m Tc-sestamibi scan on delayed imaging sho-
wed a zone of intensive increased activity in the left
thyroid inferior pole, highly suggestive of parathyroid
adenoma (Fig. l).
The woman was admitted to hospital for parathy-
roid surgery. During exploration of the neck, an 8 mm
Figure 2. Microscopic appearance of the tumour, showing
parathyroid tissue composed of uniform cells with eosinophilic
granular cytoplasm, supported by abundant vascular stroma,
scattered oxyphilic cells and foci of follicular structure containing
a colloid-like material, also visible. Chief cell adenoma
Rycina 2. Mikroskopowy obraz guza przedstawiający tkankę
przytarczycy złożoną z jednolitych komórek z eozynofilowymi
ziarnistościami w cytoplazmie otoczonych przez podścielisko
naczyniowe, rozproszone komórki oksyfilowe oraz ogniska struktur
pęcherzykowych wypełnionych płynem koloidopodobnym
Figure 1. Parathyroid scintigraphy study of the patient, showing
parathyroid adenoma
Rycina 1. Badanie scyntygraficzne przytarczyc ujawniające
gruczolak przytarczycy
tumour was found in the inferior left parathyroid gland,
and this was removed completely. The superior left pa-
rathyroid and both right parathyroid glands seemed to
be normal. Intraoperative frozen section analysis con-
firmed the diagnosis of parathyroid adenoma. Final pa-
thological diagnosis was the same (Fig. 2).
Postoperatively, investigations showed a decrease
in serum calcium level to 7 mg/dl, phosphorus to
1.2 mg/dl and magnesium to 1.5 mg/dl, suggestive of
hungry bone syndrome. Treatment was initiated with
4 g of calcium forte and 0.5 mcg of calcitriol daily.
The patient had an uneventful recovery and was di-
scharged from hospital with an acceptable calcium le-
vel (8.5 mg/dl).
Discussion
Diagnosis of hyperparathyroidism is usually first sug-
gested by the finding of an elevated serum calcium
concentration, and if hypercalcaemia is confirmed by
a repeated sample, all of its causes should be consi-
dered. The serum parathyroid hormone concentra-
tion should then be measured and the diagnosis of
primary hyperparathyroidism (PHP) is usually made
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by finding an inappropriately elevated serum para-
thyroid hormone (PTH) concentration associated
with hypercalcaemia [1].
Turner’s Syndrome is the most common cause of
short stature in otherwise healthy girls other than familial
short stature or constitutional delay of growth and matu-
rity. It is unclear whether patients with TS have an incre-
ased risk of osteoporosis or fractures [2–5]. Their bones
appear osteopoenic on radiographic evaluation and their
regional bone mass is often, but not always, below that of
age-matched, but not height-matched, controls [4].
The causes of low bone mass density (BMD) in TS
consist of hypogonadism-induced osteoporosis, oste-
omalacia (especially in countries where vitamin D defi-
ciency is more prevalent) and rarely PHP. It seems that
the presence of normocalcaemia in our patient had been
related to the coincidence of osteomalacia and under-
lying PHP, a stage which may be referred to as normo-
calcaemic hyperparathyroidism. After initiation of calcium
and vitamin D, the patient’s serum calcium level incre-
ased as a result of the prominence of PHP (hypercalca-
emic hyperparathyroidism).
A review of the literature indicates that a coincidence
of PHP and TS is very rare. We searched PubMed with
related key words of “primary hyperparathyroidism,”
“Turner syndrome” and “bone disease.” In 1993 a case of
PHP due to parathyroid adenocarcinoma in a patient
with TS was reported by Chen JF et al. [6]. This was a 45-
year-old woman who presented with primary amenorr-
hea and poor development of secondary sexual charac-
teristics and had experienced repeated bone fractures,
weight loss and associated thyrotoxicosis. She underwent
parathyroid surgery. In 1996 Francois et al. reported a
case of TS with nephrolithiasis and hypercalcaemia [7].
In 2003, Kishida et al. reported a 46-year-old female with
TS and hyperparathyroidism admitted to hospital becau-
se of severe hypercalcaemia. During medical treatment
she died of acute necrotising pancreatitis [8].
The question is now raised as to whether TS with
signs and symptoms of osteomalacia and normocalca-
emia needs to be followed to rule out PHP. We recom-
mend that serum calcium levels should be monitored
in a patient with TS and normocalcaemia during treat-
ment of osteoporosis or osteomalacia.
Conclusion
Our patient with a primary diagnosis of osteomalacia was
initially treated by calcium and vitamin D supplements.
Despite treatment, serum calcium was raised in follow-
up. This is an unusual finding during the treatment of oste-
omalacia and its presence should signal the probability of
underlying hyperparathyroidism and the need for further
evaluation. The case presented here would seem to be
noteworthy, not only for the rarity of the association of
Turner’s syndrome and hyperparathyroidism, but also for
the overlap of bone disease in both disorders. It should be
mentioned that during treatment for osteoporosis or oste-
omalacia in a patient with Turner’s syndrome serum cal-
cium levels should be detected and followed. In the event
of serum calcium rising with treatment, the presence of
an underlying hyperparathyroidism should always be
considered, rare though this association may be.
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